KN046 + nab-paclitaxel

KN046 + nab-paclitaxel is a combination therapy consisting of KN046, a recombinant humanized bispecific antibody targeting both PD-L1 and CTLA-4, and nab-paclitaxel, an albumin-bound formulation of the chemotherapy agent paclitaxel. - **KN046** acts as an immune checkpoint inhibitor by simultaneously blocking the PD-L1/PD-1 pathway and CTLA-4 pathway, thereby enhancing T-cell mediated anti-tumor immunity. - **Nab-paclitaxel** is a nanoparticle albumin-bound form of paclitaxel that allows for solvent-free delivery and improved tumor penetration via albumin-mediated transport. Nab-paclitaxel disrupts microtubule function in cancer cells leading to cell cycle arrest and apoptosis. This combination has shown favorable efficacy with tolerable toxicity in phase II trials for first-line treatment of metastatic triple-negative breast cancer (TNBC), with ongoing studies in other cancers such as pancreatic ductal adenocarcinoma (PDAC)[1][2][3][4][5].

Brand names

Abraxane

Other names

albumin-bound paclitaxel